Roche’s phase II/III SKYSCRAPER-06 study of tiragolumab plus Tecentriq & chemotherapy in metastatic non-squamous NSCLC did not meet primary endpoints

Roche's phase II/III SKYSCRAPER-06 study evaluating tiragolumab with Tecentriq (atezolizumab) and chemotherapy as a first-line treatment for untreated non-squamous non-small cell lung cancer did not meet its primary endpoints of progression-free survival (PFS) and overall survival (OS) in initial analyses. The combination therapy showed inferior efficacy compared to pembrolizumab plus chemotherapy in the intent-to-treat population of 542 patients across multiple global sites. Safety profiles remained consistent without new concerns identified. The study will be halted, with results to be shared with investigators and health authorities and presented at an upcoming medical conference.

Tiragolumab, an investigational immune checkpoint inhibitor targeting TIGIT, aims to enhance immune responses synergistically with Tecentriq, which inhibits PD-L1 to activate T-cells. Tecentriq is approved for various challenging cancers and is administered intravenously or subcutaneously in over 40 countries, offering potential in combination therapies across a broad cancer spectrum.